Decastatin, a Novel Non-Collagenous 1 Domain From Collagen Type X, Harbors a Specific Fragment With Antiangiogenic...

Area of Science:

• Biochemistry and Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Collagen NC1 domains exhibit antiangiogenic properties, making them therapeutically relevant for cancer treatment.
• Previous clinical trials with endostatin and similar NC1 domains have yielded limited success.
• Understanding the structure-activity relationship of these domains is crucial for developing effective antiangiogenic therapies.

Purpose of the Study:

• To deconstruct collagen NC1 domains using evolutionary conservation to understand their antiangiogenic potential.
• To identify novel antiangiogenic peptides derived from collagen NC1 domains.
• To investigate the role of conserved regions within NC1 domains in mediating antiangiogenic activity.

Main Methods:

• Comparative sequence analysis and homology exploration of collagen NC1 domains, including collagen type X (decastatin) and collagen type VIII (vastatin).
• Molecular deconstruction of endostatin, vastatin, and decastatin into peptide fragments.
• In vitro testing of peptide fragments using a human umbilical vein endothelial cell-based tube formation assay to assess antiangiogenic potency.

Main Results:

• Decastatin, the NC1 domain of collagen type X, showed significant homology to vastatin.
• Peptide fragments containing conserved regions demonstrated signaling and antiangiogenic activity.
• Decastatin fragment 4 (D4) exhibited the highest antiangiogenic potency (IC50 = 2.7 μM), comparable to intact NC1 domains. Vastatin fragment 4 (V4) also showed inhibitory effects.

Conclusions:

• Evolutionary conservation is a valuable tool for identifying novel antiangiogenic NC1 domain fragments.
• The antiangiogenic activity of NC1 domain-derived peptides is localized within their conserved regions.
• Decastatin fragment 4 (D4) represents a promising novel antiangiogenic therapeutic candidate for cancer treatment.